Yantai Dongcheng Pharmaceutical Group (002675) Fundamentals 2026 — P/E 51.0x, Revenue Analysis | SniperIQ
Yantai Dongcheng Pharmaceutical Group (002675) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥10.4B, trading at ¥12.64 on the SHZ. This SniperIQ fundamentals page covers Yantai Dongcheng Pharmaceutical Group's valuation (P/E 51.0x, P/B 2.4x), profitability (net margin 7.6%), revenue (¥2.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yantai Dongcheng Pharmaceutical Group's market cap?
Yantai Dongcheng Pharmaceutical Group (002675) has a market capitalization of approximately ¥10.4B, trading at ¥12.64 on the SHZ. Market cap moves with the live share price.
What is Yantai Dongcheng Pharmaceutical Group's P/E ratio?
Yantai Dongcheng Pharmaceutical Group's trailing twelve-month P/E ratio is 51.0x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Yantai Dongcheng Pharmaceutical Group?
Yantai Dongcheng Pharmaceutical Group runs a net profit margin of 7.6%, a gross margin of 52.0%, and an operating margin of 13.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yantai Dongcheng Pharmaceutical Group generate?
Yantai Dongcheng Pharmaceutical Group reported revenue of ¥2.7B for fiscal year 2025, with net income of ¥196M and earnings per share (EPS) of 0.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yantai Dongcheng Pharmaceutical Group pay a dividend?
Yantai Dongcheng Pharmaceutical Group offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Yantai Dongcheng Pharmaceutical Group financially healthy?
Yantai Dongcheng Pharmaceutical Group carries a debt-to-equity ratio of 0.27x and a current ratio of 1.71x, with a market beta of -0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yantai Dongcheng Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yantai Dongcheng Pharmaceutical Group (002675) the key facts are: market cap ¥10.4B, P/E 51.0x, revenue ¥2.7B, 52-week range 12.05-18.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Yantai Dongcheng Pharmaceutical Group's full fundamentals live
Get Yantai Dongcheng Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.